<DOC>
	<DOCNO>NCT02032823</DOCNO>
	<brief_summary>Olaparib treatment patient germline BRCA1/2 mutation high risk HER2 negative primary breast cancer complete definitive local treatment neoadjuvant adjuvant chemotherapy</brief_summary>
	<brief_title>Olaparib Adjuvant Treatment Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer</brief_title>
	<detailed_description>Patients randomise 1:1 ratio either olaparib placebo . Randomisation stratify Hormone receptor status ( ER and/or PgR positive/HER2 negative versus TNBC ) , prior neoadjuvant versus adjuvant chemotherapy prior platinum use breast cancer . Randomised patient receive study treatment maximum 12 month . All patient safety assessment every 2 week first month , every 4 week follow 5 month 3 monthly remain 6 month study treatment plus 30 day discontinuation . Following randomisation , patient assess regularly sign , symptom evidence disease recurrence take medical history , physical examination mammogram/breast MRI . Efficacy assessment perform 3 monthly basis first 2 year , follow 6 monthly assessment year 3 , 4 5 annually thereafter . All patient ( except bilateral mastectomy ) mammogram / breast MRI annually 10 year begin 6 month randomisation . All randomise patient clinical assessment visit 10 year follow randomisation study . Once patient complete 10 year clinical assessment enter survival follow phase trial continue 10 year last patient randomise .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically confirm nonmetastatic primary invasive adenocarcinoma breast one follow phenotype : 1 . Triple negative breast cancer define : ER PgR negative AND HER2 negative ( eligible antiHER2 therapy ) 2 . ER and/or PgR positive , HER2 negative Documented germline mutation BRCA1 BRCA2 predict deleterious suspect deleterious ( know predict detrimental/lead loss function ) . Completed adequate breast axilla surgery . Completed least 6 cycle neoadjuvant adjuvant chemotherapy contain anthracyclines , taxanes combination . Prior platinum potentially curative treatment prior cancer ( e.g . ovarian ) adjuvant neoadjuvant treatment breast cancer allow . ECOG 01 . Exclusion criterion : Any previous treatment PARP inhibitor , include olaparib and/or know hypersensitivity excipients study treatment . Patients second primary malignancy . EXCEPTIONS : 1. adequately treated nonmelanoma skin cancer , curatively treated situ cancer cervix , Ductal Carcinoma situ ( DCIS ) breast , stage 1 grade 1 endometrial carcinoma 2. solid tumour lymphomas ( without bone marrow involvement ) diagnose â‰¥ 5 year prior randomisation treat evidence disease recurrence one line chemotherapy apply . Concomitant use know potent CYP3A inhibitor ketoconazole , itraconazole , ritonavir , indinavir , saquinavir , telithromycin , clarithromycin nelfinavir Evidence metastatic breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Olaparib</keyword>
	<keyword>BRCA 1/2</keyword>
	<keyword>HER2</keyword>
</DOC>